Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma and in a Phase 1/2 clinical trial in multiple tumor types. In addition, the company’s products under development include IMC-R117C (PIWIL-1) that is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, including colorectal cancer; IMC-P115C (PRAME-HLE-A02) that is in Phase 1 clinical trial for patients with tumors that express PRAME; IMC-M113V that is in Phase 1 clinical trials for a potential functional cure in human immunodeficiency virus (HIV); and IMC-I109V that is in Phase 1 clinical trials for a potential functional cure in hepatitis B virus (HBV). Further, it develops IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-S118AI to treat type 1 diabetes; and IMC-U120AI to treat atopic dermatitis. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Market Valuation | Analysts set average price target at $60, reflecting confidence in Immunocore's potential despite current trading near 52-week low of $27.19 |
Pipeline Challenges | Learn about setbacks in brenetafusp development, with peak sales estimates reduced by 42% to $5.4 billion, highlighting risks in drug development |
HIV Breakthrough? | Delve into IMC-M113V's promising Phase 1 data for HIV treatment, showcasing dose-dependent viral control and favorable safety profile |
Kimmtrak's Triumph | Explore Immunocore's success with Kimmtrak in metastatic uveal melanoma, driving impressive revenue growth and establishing a strong market position |
Metrics to compare | IMCR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMCRPeersSector | |
---|---|---|---|---|
P/E Ratio | −68.4x | −0.5x | −0.5x | |
PEG Ratio | −1.03 | 0.01 | 0.00 | |
Price / Book | 3.9x | 0.4x | 2.6x | |
Price / LTM Sales | 4.4x | 5.5x | 2.9x | |
Upside (Analyst Target) | 121.6% | 633.5% | 53.0% | |
Fair Value Upside | Unlock | 20.5% | 8.9% | Unlock |